This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ImmunoGen, Inc. Announces Presentations By Company Scientists At Upcoming AACR Annual Meeting

ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the presentations scheduled to be made by Company scientists at the American Association for Cancer Research (AACR) Annual Meeting to be held April 5-9, 2014 in San Diego, CA.

“The presentations scheduled include the pharmacokinetics modeling work which informed our decision to dose IMGN853 based on adjusted ideal body weight and to assess it dosed weekly,” commented John Lambert, Ph.D., Executive Vice President and Chief Scientific Officer. “They also include highly encouraging preclinical findings with both our IMGN289 and IMGN853 compounds, as well as data on some of the more recent additions to our ADC technology portfolio.”

ImmunoGen has advanced three novel, wholly owned product candidates into clinical testing in the past two years. IMGN853, which targets folate receptor α (FRα), is a potential treatment for ovarian, endometrial and other FRα-positive solid tumors. IMGN289, which targets EGFR, is a potential treatment for head and neck, lung and other EGFR-positive solid tumors. IMGN529, which targets CD37, is a potential treatment for CD37-positive B-cell malignancies. Abstracts with IMGN853 and IMGN529 clinical data have been submitted for presentation at an upcoming medical conference.

ImmunoGen Poster Presentations Scheduled

Sunday, April 6:
  • Abstract #667 “IMGN853, a folate receptor (FR) α-targeting antibody-drug conjugate (ADC), is highly effective against xenograft models with clinically relevant levels of receptor expression” (1:00-5:00pm PT, Poster Section 28, Poster Board Number 24)

Monday, April 7:
  • Abstract #1618 “New peptide-linked anilino-maytansinoid antibody-drug conjugates (ADCs) for the treatment of cancer” (8:00am-12:00pm PT, Poster Section 27, Poster Board Number 1)
  • Abstract #2644 “Antibody-drug conjugates (ADCs) with a novel DNA-alkylating agent, DGN462, are highly potent in vitro and in vivo against human cancer models” (1:00-5:00pm PT, Poster Section 31, Poster Board Number 5)

Tuesday, April 8:
  • Abstract #4513 “IMGN289, an EGFR-targeting antibody-drug conjugate, is effective against tumor cells that are resistant to EGFR tyrosine kinase inhibitors” (1:00-5:00pm PT, Poster Section 29, Poster Board Number 23)
  • Abstract #4641 “Development of modified dosing approaches to achieve specific pharmacokinetic (PK) objectives in the first-in-human phase I clinical trial of IMGN853, a folate receptor α-targeting antibody drug conjugate” (1:00-5:00pm PT, Poster Section 35, Poster Board Number 35)

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company’s ADC technology uses a tumor-targeting engineered antibody to deliver one of ImmunoGen's highly potent cancer-cell killing agents specifically to tumor cells; the Company has also developed antibodies with anticancer activity of their own. The most advanced compound with ImmunoGen’s ADC technology is Roche’s Kadcyla ®. Additional compounds are in clinical testing by ImmunoGen and through the Company’s partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi. More information about ImmunoGen can be found at

Kadcyla ® is a registered trademark of Genentech, Inc., a member of the Roche Group.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,798.49 -14.90 -0.08%
S&P 500 2,090.11 +1.24 0.06%
NASDAQ 5,127.5250 +11.3820 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs